Omega-3 may impair traumatic brain injury recovery, study finds

A study has linked the omega-3 fatty acid eicosapentaenoic acid (EPA) to impaired healing after repeated traumatic brain injuries, exploring the role of the fatty acids in brain health and how formulators can better take into account ratios of these compounds when designing cognitive health products. 

Nutrition Insight discusses the study results with co-author, Onder Albayram, Ph.D., an associate professor in the Department of Medicine, Department of Pathology and Laboratory, and Department of Neuroscience at the Medical University of South Carolina, US. 

In neuroscience, it is still unknown whether omega-3 brings resilience or resistance to the brain, explains Albayram, noting that this is the first study in this field.

“What surprised us most was that EPA appeared to be biologically engaged in the injured brain in a way that coincided with impaired vascular repair. The cerebrovascular system is extensive and highly active, and after brain injury, it plays an important role in oxygen delivery, metabolic support, and tissue repair.”

He continues that in human Chronic Traumatic Encephalopathy (CTE) tissue, the researchers observed changes in polyunsaturated fatty acid handling, as well as in how vascular and fatty acid metabolism-related genes were expressed, suggesting that the injured or diseased brain may process these lipids differently from a healthy brain. 

“Our study focused on repetitive injury and CTE-relevant biology, so we cannot yet determine whether the same process occurs after a single traumatic brain injury. That will be an important question for future studies.”

The study is published in Cell Reports. Albayram tells us more about the study findings of one of the most used brain supplements globally, while advising what formulators should keep in mind.

Based on these findings, how do you see the role of omega-3 fatty acids evolving in brain health supplements, especially for post-injury recovery?

Albayram: EPA should not be viewed simply as good or bad for the brain. Our study suggests that the brain’s response to EPA may depend on biological context, particularly after injury, when vascular repair and metabolic demands are changing. 

EPA should not be viewed simply as good or bad for the brain, says Albayram.These findings should not cause concern about omega-3 supplements in general, but they do suggest that EPA and docosahexaenoic acid (DHA) should not always be treated as interchangeable ingredients. For post-injury recovery, we need more careful, evidence-based studies to understand when omega-3 exposure may be helpful, when it may be neutral, and when a specific formulation could potentially interfere with the brain’s repair process.

Given the findings of impaired vascular repair following EPA exposure after traumatic brain injury, how might this influence product formulations targeting brain health?

Albayram: The main implication is that formulation may matter. EPA and DHA have different biological properties, and our findings suggest that these differences could become important in conditions where the brain is undergoing repair. In nutrition and medicine, fish oil or omega-3 exposure is already considered carefully in some contexts, such as surgery, wound healing, or tissue repair, although much more work is needed to understand how this applies to the brain. 

For brain health products, the field should move toward more precise formulations that consider dose, EPA to DHA ratio, timing, and the biological state of the person using the supplement, rather than assuming that all omega-3 combinations are equally appropriate for every situation.

Can these findings suggest that EPA may impact other neurological problems?

Albayram: It would be premature to generalize too broadly at this stage. This study took several years and combined in vivo, in vitro, and human tissue analyses, which reflects how carefully these questions need to be studied. To understand whether EPA has similar relevance in other neurological or psychiatric conditions, we would first need to know how central the cerebrovascular system is to each disease, which cell types are involved, and whether similar metabolic mechanisms are present.

That said, this work raises an important broader question. Many neurological and psychiatric conditions develop silently over time, and individual brains may differ in their vulnerability. Brain injury may serve as a useful model for studying how metabolic inputs, including dietary lipids, interact with stressed or vulnerable neural systems. EPA may be one important entry point into this broader area, but careful, disease-specific studies will be essential.

What should the nutrition industry keep in mind when formulating with omega-3 fatty acids for brain injury recovery? 

Albayram: One key point is that omega-3 fatty acids should not be considered interchangeable, and formulations should reflect that. There is already some recognition of this in early life nutrition, where DHA is often prioritized, suggesting that different omega-3 components can serve different biological roles. Our findings support the need to evaluate EPA and DHA separately, especially when the brain is undergoing repair. 

Formulations should reflect that omega-3 fatty acids should not be considered interchangeable.At the same time, omega-3 fatty acids are important dietary nutrients, and dietary intake remains essential because the body does not synthesize them efficiently. The challenge is that under stress or injury, the way the brain processes and uses these lipids may change. This may be especially relevant for mild or concussive brain injury, where repair processes can be subtle and prolonged. Preclinical findings like ours should be followed by careful clinical studies, and formulations should consider timing, dose, and biological context rather than assuming the same benefit across all injury types.

What are the potential challenges in marketing omega-3 products for brain health, considering EPA’s role in neurovascular dysfunction?

Albayram: One challenge is balancing the long-standing public perception that omega-3 supplements are broadly beneficial with emerging evidence that their effects may depend on biological context. The supplement market is highly accessible and rapidly expanding, but for brain health, especially in conditions with silent or early-stage pathology, we still have limited guidance on how different formulations may influence long-term outcomes. This creates a gap between production, marketing, and mechanistic science. 

Many neurological and psychiatric conditions have long asymptomatic phases, and we do not yet fully understand how supplement use during these periods may affect disease trajectories. 

As a result, product messaging should be careful not to oversimplify complex biology. Moving forward, closer alignment between scientific research and product development will be important, with greater emphasis on transparency, evidence-based claims, and context-aware recommendations.

What safety measures should companies take when developing brain health products?

Albayram: One challenge is that safety frameworks for supplements, especially for brain health, are often based on evidence generated in different systems and under different conditions. That evidence can be useful, but it may not always capture how a formulation behaves in a specific biological context, such as the injured or recovering brain.

More collaborative research between academic groups and industry would help define safety boundaries under controlled conditions. This is especially important for lipid-based supplements, because the brain is highly sensitive to lipid metabolism. Safety should not only mean avoiding toxicity, but also understanding how a compound interacts with the brain’s metabolic and repair systems under different physiological and disease conditions.

What opportunities exist for innovation in nutritional supplements aimed at improving recovery post-traumatic brain injury, given the context of EPA’s role in the process? 

Albayram: One opportunity is to shift the conversation from treatment alone toward prevention, recovery support, and biological context. Much of brain research has focused on finding a target and developing a therapy after the disease has already progressed. That remains important, but many neurological conditions develop over long silent periods, and we need to better understand how nutrition may influence those early or vulnerable stages.

Safety should mean avoiding toxicity and understanding how a compound interacts with the brain’s metabolic and repair systems.Our findings suggest that metabolic context, including how the brain handles lipids during recovery, may affect repair trajectories. Innovation may come from designing nutritional strategies that support the brain’s own repair capacity rather than assuming that more of a given compound is always better. In that sense, EPA is not simply a risk factor or a therapeutic agent. It is a reminder that timing, formulation, and biological state matter. This could open the door to more precise and context-aware nutritional approaches.

How can manufacturers ensure that their omega-3 formulations are beneficial and contextually appropriate for individuals recovering from brain injury?

Albayram: One important step is to avoid overly simple claims such as “beneficial” or “neuroprotective” without clearly defining the context. Our work suggests that the injured brain may handle fatty acids differently from the healthy brain, particularly at the level of metabolism and vascular support.

Manufacturers can help by communicating these nuances clearly and by supporting studies that define when specific formulations may be appropriate. This includes considering the balance between EPA and DHA, the timing of supplementation, and the physiological state of the individual. 

The brain normally relies heavily on glucose metabolism, with more limited use of fatty acid pathways under baseline conditions. When this balance changes during injury or disease, the response to lipid-based supplements may also change. In that sense, benefit depends not only on product composition, but also on matching that composition to the biological context in which it is used.